Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension

Hypertension Research

Volumn 20, Issue 2, 1997, Pages 85-90

  Tanabe, Akiyo ^a   Naruse, Mitsuhide ^a   Naruse, Kiyoko ^a   Hase, Mitsuyasu ^a   Yoshimoto, Takanobu ^a   Tanaka, Masami ^a   Seki, Toshiro ^a   Demura, Reiko ^a   Demura, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Echocardiography; Left ventricular hypertrophy; Left ventricular mass index; Primary aldosteronism

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DOPPLER ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM;

EID: 0030805573     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.20.85     Document Type: Article

References (27)

1. Laragh JH, Baer L, Brunner HR, et al: Renin, angiotensin, and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-652.
2. Mueller FB, Laragh JH: Clinical evaluation and differential diagnosis of the individual hypertensive patient. Clin Chem 1991; 37 (10 Pt 2): 1868-1879.
3. Laragh JH, Ulick S, Januszewtcz W, et al: Aldosterone secretion and primary and malignant hypertension. J Clin Invest 1960; 39: 1091-1096.
4. Conn JW: Plasma renin activity in primary aldosteronism: importance in differential diagnosis and in research of essential hypertension. JAMA 1964; 190: 222-225.
5. Beevers DG, Brown JJ, Ferriss JB, et al: Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med 1976; 179: 401-410.
6. Pringle SD, Macfarlane PW, Isles CG, et al: Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism. J Hum Hypertens 1988; 2: 157-159.
7. Janota T, Hradec J, Kral J: Heart in adrenal diseases. Cor Vasa 1992; 34: 115-122.
8. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Circulation 1991; 83: 1849-1865.
9. Abe M, Hamada M, Matsuoka H, et al: Myocardial scintigraphic characteristics in patients with primary aldosteronism. Hypertension 1994; 23 (Suppl): I-164-I-167.
10. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23: 869-877.
11. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
12. Koren MJ, Devereux RB, Casale PN, et al: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
13. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575.
14. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A.
15. Koren MJ, Devereux RB: Mechanism, effects, and reversal of left ventricular hypertrophy in hypertension. Curr Opin Nephrol Hypertens 1993; 28: 87-95.
16. Labovitz AJ, Pearson AC: Evaluation of left ventricular diastolic function: clinical relevance and recent Doppler echocardiographic insights. Am Heart J 1987; 114: 836-851.
17. Massie BM, Tuban JF, Szlachcic J, et al: Hypertensive heart disease: the critical role of LV hypertrophy. J Cardiovasc Pharmacol 1989; 13 (Suppl 1): 18-24.
18. Anversa P, Ricci R, Olivetti G: Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. J Am Coll Cardiol 1986; 7: 1140-1149.
19. De Simone G, Devereux RB, Roman MJ, et al: Echocardiographic LV mass and electrolyte intake predict arterial hypertension. Ann Intern Med 1991; 114: 202-209.
20. Duprez AD, Bauwens FR, De Buyzere ML, et al: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17A-20A.
21. Klug D, Robert V, Swynghedauw B: Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993; 71: 46A-54A.
22. Sun Y, Weber KT: Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med 1993; 122: 404-411.
23. Brilla CG, Pick R, Tan LB, et al: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 67: 1355-1364.
24. Jalil JE, Janicki JS, Pick R, et al: Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens 1991; 4: 51-55.
25. Levy D, Anderson KM, Savage DD, et al: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med 1988; 108: 7-13.
26. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-1566.
27. Devereux RB, Koren MJ, De Simone G, et al: Left ventricular mass as a measure of preclinical hypertensive disease. Am J Hypertens 1992; 5 (6 Pt 2): 175s-181s.